Tofacitinib, a pan-JAK inhibitor, used in the treatment of rheumatoid arthritis, ulcerative colitis et al, inhibits IFN- I production by suppressing transcription and nuclear translocation of IRF7, and affects DCs activities. The gene discussed is IRF7; the disease is rheumatoid arthritis.